Our overall focus is to create and maximize value for promising therapeutic approaches originating from academic labs or biotechnology companies. We provide competent drug discovery and development expertise combined with financing, from target to clinical proof of concept.
Our model is flexible. Projects can enter or exit the pipeline at various stages of development. They are led according to industry standards, lowering execution risk and maximizing value creation and the chances of commercial success. At predetermined development stages, the projects are out-licensed to pharma partners for further development or they serve to generate new companies around solid assets.
Scout for new projects by interacting closely with academic labs, biotechnology companies, technology transfer offices, and other valorization structures interested in therapeutic innovation, particularly in the discovery of novel medication for innovative targets.
Reinvest the benefits from the out-licensing in our R&D fund to support new projects and thus returning value to our partners and the community.
Define the optimal development strategy for each new project with the help of our dedicated drug discovery and development experts and our international Scientific Advisory Board.
Implement the agreed strategy to reach key milestones where the project can be out-licensed or used to create start-up companies. Project activities are outsourced and conducted in the relevant contract research organizations (CROs) within our facilities in Saint-Laurent or Laval, or elsewhere.
Our portfolio is managed according to industry standards, reducing the execution risk and maximizing value creation and the chances of commercial success.